All In Biotech

Drug Trial Radar · NCT01623596

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.

A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)

Last checked: Nov 20, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 881 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

881

Actual

Start

Jun 8, 2012

Primary completion

Jul 13, 2015

Study completion Jul 13, 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 20, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy. Patients will be be treatment naive or have only been treated with one class of DMT (Interferon beta preparation or glatiramer acetate) . Patients will be able to switch to different treatment for safety, efficacy, tolerability or convenience during the study. Primary objective is to evaluate efficacy of fingolimod by assessing patients retention on treatment. Secondary objectives are to compare reasons for discontinuation, adverse events, cognitive impairment, medication satisfaction and change in brain volume measured by MRI.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

  • FingolimodDrug

  • Disease Modifying therapyDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participant Retention Rate Over 12 MonthsTime frame: at 12 months

Locations

123 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Cullman, Alabama

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Sun City, Arizona

  • Novartis Investigative Site

    Tucson, Arizona

  • Novartis Investigative Site

    Sherwood, Arkansas

  • Novartis Investigative Site

    Fullerton, California

  • Novartis Investigative Site

    Oceanside, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Walnut Creek, California

  • Novartis Investigative Site

    Basalt, Colorado

  • Novartis Investigative Site

    Boulder, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Denver, Colorado

  • Novartis Investigative Site

    Fort Collins, Colorado

  • Novartis Investigative Site

    Fairfield, Connecticut

  • Novartis Investigative Site

    New London, Connecticut

  • Novartis Investigative Site

    Dover, Delaware

  • Novartis Investigative Site

    Atlantis, Florida

  • Novartis Investigative Site

    Bradenton, Florida

  • Novartis Investigative Site

    Delray Beach, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    North Palm Beach, Florida

  • Novartis Investigative Site

    Plantation, Florida

  • Novartis Investigative Site

    Pompano Beach, Florida

  • Novartis Investigative Site

    Port Charlotte, Florida

  • Novartis Investigative Site

    Port Orange, Florida

  • Novartis Investigative Site

    Sarasota, Florida

  • Novartis Investigative Site

    Sarasota, Florida

  • Novartis Investigative Site

    St. Petersburg, Florida

  • Novartis Investigative Site

    Tallahassee, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    West Palm Beach, Florida

  • Novartis Investigative Site

    Atlanta, Georgia

  • Novartis Investigative Site

    Columbus, Georgia

  • Novartis Investigative Site

    Decatur, Georgia

  • Novartis Investigative Site

    Suwanee, Georgia

  • Novartis Investigative Site

    Flossmoor, Illinois

  • Novartis Investigative Site

    Northbrook, Illinois

  • Novartis Investigative Site

    Anderson, Indiana

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.